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Alpha-adrenergic-mediated coronary vasoconstriction
during stress such as cold pressor testing may contribute
to myocardial ischemia by increasing coronary vascular
resistance in patients with severe coronary artery dis-
ease. Nonselective alpha.receptor blockade with phen-
tolamine abolishes both the peripheral and coronary va-
soconstriction during cold pressor testing, but causes
reflex tachycardia and increased inotropy. To determine
the role of selectivealphaj-reeeptor blockade, the changes
in coronary vascular resistance during cold pressor test-
ing were measured in 18 patients with coronary artery
disease before and after intravenous administration of
100 mg of trimazosin. Cold pressor testing was per-
formed at a constant paced subanginal heart rate of 95
± 5 beats/min (± 1 SD). Before trimazosin, cold pressor
testing increased mean arterial pressure by 92: 4% (102
± 14 to 111 ± 14 mm Hg, p < 0.001) with no change
in coronary sinus blood flow, but significantly increased
coronary vascular resistance by 15 ± 19% (1.02 ± 0.46
to 1.]5 2: 0.57 units, p < 0.05). Five minutes after
trimazosin, cold pressor testing increased mean arterial
pressure by 6 ± 5% (p < 0.001) with a marked atten-
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uation of the increase in coronary vascular resistance (6
± 11%, P = NS), which was significantly less than
before trimazosin (p < 0.02). Trimazosin did not in-
crease plasma norepinephrine concentration at rest, sug-
gesting that in the dosage used trimazosin caused selec-
tive alphaj-receptor blockade.
These data suggest that although the hypertensive
response to cold pressor testing is somewhat blunted by
selective alphaj-adrenoceptor blockade, the reflex coro-
nary vasoconstriction during adrenergic stimulation in
some patients with coronary artery disease can be sig-
nificantly attenuated. Use of agents that block alphar
adrenoceptors has been clinically unsatisfactory because
of the adverse myocardial effects of increased norepi-
nephrine release. Selective alphaj-receptor blockade may
have an additional advantage over nonselective alpha-
adrenergic blockade in that the release of norepineph·
rine is also attenuated, thus potentially producing less
augmentation of heart rate and myocardial oxygen
demand.
(J Am Coil CardioI1985;5:840-6)
Alpha-adrenergic-mediated coronary vasoconstriction dur-
ing stress such as cold pressor testing may contribute to
myocardial ischemia in patients with coronary artery disease
(1.2). Extensive investigations (3-9) have documented the
role of alpha-adrenergic vasoconstriction on coronary blood
flow. Increased alpha vasoconstrictor tone has been impli-
cated in the exacerbation of coronary spasm after subcu-
taneous administration of epinephrine in patients receiving
propranolol (10). Beta-receptor blockade with propranolol
has been reported to intensify the duration of myocardial
ischemia and ventricular ectopic activity in patients with
vasospastic angina pectoris , presumably through inhibition
of betaj-receptor-mediated coronary vasodilation, resulting
in unopposed alpha-adrenergic-mediated vasoconstriction
(II) . Recently, potentiation of alpha vasoconstrictor activity
has been demonstrated after acute beta-adrenergic blockade
during cold pressor testing (12).
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Clinical application of nonselective alpha-adrenergic an-
tagonists , such as phentolamine, as vasodilators has been
unsatisfactory because of the increased circulating norepi-
nephrine after blockade of alpha-receptors, increasing the
heart rate, contractility and myocardial oxygen consumption
(13) . We speculated that selective alpha I-receptor blockade
might inhibit coronary vasoconstriction without inducing the
associated adverse myocardial effects of nonselective alpha-
receptor blockade. Accordingly, the purpose of this inves-
tigation was to determine whether selective alpha .-receptor
blockade with trlmazosin could attenuate the inappropriate
reflex increase in coronary vascular resistance during the
adrenergic stimulation of cold pressor testing.
Methods
Study patients. Eighteen patients undergoing diagnostic
cardiac catheterization for chest pain were studied. Patients
were excluded who had unstable angina, coexistent valvular
heart disease, myocardial infarction within 6 weeks of study ,
severe left ventricular dysfunction , greater than 50% left
main coronary artery stenosis, concomitant treatment with
calcium channel blocking drugs or nonsteroidal anti-inflam-
matory drugs or contraindication to the use of alpha-ad-
renergic blocking agents .
Study protocol. The investigational protocol and con-
sent form were approved by the Human Subjects Committee
of the Brigham and Women 's Hospital. After written in-
formed consent was obtained, treatment with beta-adren-
ergic blocking agents was withheld in all patients at least
18 hours, and treatment with long-acting nitrate preparations
at least 6 hours before catheterization. As part of the di-
agnostic protocol, nitroglycerin, 0.4 mg sublingually, and
atropine, 0.4 mg intravenously, were given before coronary
angiography in all patients.
To minimize the metabolic and vasodilator effects of
radiographic contrast material after the completion of left
ventriculography and coronary angiograph y (14), at least
15 minutes elapsed before an 8F coronary sinus thermodi-
lution pacing catheter (Wilton Webster Laboratories) was
positioned in the coronary sinus by way of an antecubital
vein for the study protocol. Fluoroscopy confirmed proper
location and the stable coronary sinus catheter position dur-
ing the study . Mean and phasic arterial pressures were mea-
sured with a femoral artery catheter. Arterial and coronary
sinus blood oxygen content was measured using a fuel cell
method (Lex-Or-Con , Lexington Instruments) . Arterial and
coronary sinus blood for lactate concentration was deter-
mined by standard enzymatic assay. All pressures , coronary
flow signals and electrocardiogram were recorded on a mul-
tichannel optical strip chart recording system (Electronics
for Medicine) .
Cold pressure testing. Ten minutes after placement of
the coronary sinus catheter, measurements of phasic and
mean arterial pressure, heart rate , coronary sinus blood flow
and arterial and coronary sinus oxygen and lactate contents
were made at rest and during cold pressor testing, before
and 5 minutes after intravenous administration of 100 mg
of trimazosin. To evaluate the effects of trimazosin after a
longer equilibration period , a third cold pressor test was
performed in eight patients 30 minutes after trimazosin
administration. Cold pressor testing was performed as in
previous studies (/,12 ,15). In brief, cold pressor testing
measurements were made during coronary sinus pacing at
a constant subanginal rate (95 ± 5 beats/min) to eliminate
the influence of heart rate changes on coronary sinus blood
flow, and at the identical paced heart rate during immersion
of the hand and forearm in ice water for 90 seconds. At
least a 5 minute equilibration period allowed hemodynamic
measurements to return to baseline values between cold
pressor testing.
Plasma norepinephrine . Femoral artery blood samples
for plasma norepinephrine determinations were collected (3
ml into reduced glutathione) before and 5 (18 patients) and
30 (8 patients) minutes after administration of triinazosin at
rest. Plasma norepinephrine was determined by radioen-
zyme assay as previously described (/6). Blood samples
were not obtained during cold pressor testing because this
stimulus is known to produce significant increases in sys-
temic and transmyocardial catecholamine concentrations
(/7 ,18) . The normal plasma norepinephrine concentration
( ± I standard deviation) in our laboratory is 213 ± 30
pg/rnl.
Data analysis. Coronary sinus blood flow was calcu-
lated from simultaneously recorded temperature signals by
the method of Ganz et al. (/9). Heart rate was calculated
from the electrocardiogram. Coronary vascular resistance
was calculated as the quotient of mean arterial pressure and
coronary sinus blood flow. Arterial-coronary sinus oxygen
content difference was expressed in milliliters of oxygen
per deciliter of blood .
Statistical analysis. The effects of trimazosin before and
after cold pressor testing were assessed by analysis of var-
iance. Whenever such analysis indicated a significant con-
tribution of a particular variable to total sample variability,
subsequent comparisons between the individual groups were
performed using the appropriate paired or nonpaired Stu-
dent's two-tailed t test. Results are expressed as mean ::t
standard deviation and a probability (p) value of less than
0.05 was regarded as statistically significant.
Results
Clinical data (Table 1). Seven of the 18 patients were
not receiving beta-receptor blocking drugs before study.
Two patients were receiving metoprolol before study; seven
patients were receiving propranolol, one patient was re-
ceiving nadolol and one was receiving timolol. Beta-recep-
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Table 1. Clinical and Hemodynamic Data in 18 Patients
Beta-
Blocking
Age (yr) Agent* RCA LAD LCx RAP PCW LVEF
Case & Sex (mg/24 h) (%) (%) (%) (mm Hg) (mmHg) (%) LVWM
I 36M 0 100 40 100 6 7 47 ApH,IA
2 46M 80,n 60 100 90 5 9 81 N
3 69F 80 0 99 0 II II 70 ApH
4 55M 480 100 70 90 8 14 64 IH
5 63M lOO,m 40 70 0 3 4 68 N
6 66M 0 90 90 80 4 7 55 AnH
7 57M 0 100 100 75 3 7 66 AnA,1O
8 55F 160 95 0 0 7 13 71 N
9 58M 480 100 99 50 5 10 76 N
10 54M 0 100 60 100 4 5 47 IA,AnH
II 59M 0 0 85 100 2 9 69 IH
12 54M 0 100 60 95 3 6 76 IH
13 63M lOO,m 100 95 0 3 9 61 10
14 43M 0 50 50 70 9 13 60 IH
15 60M 120 0 0 90 5 5 75 AnH
16 71M 40 0 50 70 2 9 64 N
17 59M 80 70 90 0 7 10 67 N
18 67M 20,t 90 60 100 2 9 45 AnH,IH
Mean ± SO 58 ± 9 5 ± 3 9 ± 3 65 ± II
*The beta-adrenergic blocking agent is propranolol unless marked with subscript: m = metoprolol, n = nadolol, t = timolol. A = akinesia; An
= anterior; Ap = apical; 0 = dyskinesia; F == female; H = hypokinesia; I = inferior; LAD = left anterior descending coronary artery; LCx = left
circumflex coronary artery stenosis; LVEF = left ventricular ejection fraction; LVWM = left ventricular wall motion abnormality; M = male; N =
normal; PeW = pulmonary capillary wedge pressure; RAP = right atrial pressure; RCA = right coronary artery.
tor blockade was withheld at least 18 hours in all patients.
Patient 2, in whom nadolol was discontinued 18 hours before
study, had similar cold pressor responses as observed in the
group data and was included in the analysis. No patient
experienced angina during the initial or subsequent cold
pressor testing. There was no difference in rest or cold
pressor testing response between patients with typical or
atypical angina pectoris.
Resthemodynamic response to trimazosin (Table 2). At
rest 5 minutes after trimazosin administration, mean arterial
pressure decreased from 98 ± 10 to 93 ± 7 mm Hg (p <
0.01 versus control) and 30 minutes after trimazosin to 88
± 6 mm Hg (p < 0.01 versus control). There was no
statistically significant increase in coronary sinus blood flow
at rest, coronary vascular resistance, serum norepinephrine
concentration or heart rate after the administration of
trimazosin.
Cold pressor hemodynamic responses to trimazosin
(Table 3). During cold pressor testing before trimazosin
administration, mean arterial pressure increased by 9% from
102 ± 14 to 111 ± 14 mm Hg (p < 0.001), with no change
in coronary sinus blood flow (l14 ± 40 to 111 ± 40 mllmin,
p = NS) and a 14% increase in coronary vascular resistance
from 1.02 ± 0.46 to 1.16 ± 0.57 units (p < 0.02).
Five minutes after trimazosin administration, cold pres-
sor testing increased mean arterial pressure by 6% (95 ±
9 to 101 ± 10 mm Hg, p < 0.001) with no change in
coronary sinus blood flow (l1O ± 49 to 112 ± 53 ml/min,
p = NS) or coronary vascular resistance (1.05 ± 0.53 to
1.11 ± 0.62 units, p = NS). The cold pressor testing
response Wassimilar 30 minutes after trimazosin. Cold pres-
sor testing 30 minutes after trimazosin administration in
eight patients increased mean arterial pressure by 4% from
92 ± 9 to 96 ± 8 mm Hg (p < 0.01) with no increase in
Table 2. Mean Rest Hemodynamics and Norepinephrine Concentration Before and After Trimazosin Administration in 18 Patients
HR MAP CSBF CVR NOR
(beats/min) (mmHg) (mllmin) (units) (pg/ml)
Control 71 ± 12 98 ± 10 105 ± 34 l.01 ± 0.34 240 ± 40
T5 74 ± 12 93 ± 9* 108 ± 46 0.93 ± 0.28 251 ± 35
no 76 ± 12 88 ± 6* 110 ± 35 0.86 ± 0.26 256 ± 50
*p < 0.01 versus control. Values represent mean ± standard deviation. CSBF = coronary sinus blood flow; CVR = coronary vascular resistance;
HR = heart rate; MAP = mean arterial pressure; NOR = serum norepinephrine concentration; T5 = 5 minutes after trimazosin; T30 = 30 minutes
after trimazosin.
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Table 3. Hemodynamic Response During Cold Pressor Testing Before and After Trimazosin Administration in 18 Patients
ABP (%) ACSF (mllmin) ACVR (units) ACVR (%)
Case C T5 no C T5 no C T5 no C T5 no
I 17 7 3 -2 0.09 0.04 15 8
2 3 3 -8 -I 0.10 0.05 12 5
3 13 6 -7 -I 0.77 0.68 33 29
4 10 3 -28 -19 0.57 0.32 54 31
5 7 15 -4 17 0.14 -0.15 12 -II
6 13 6 -3 5 0.12 0.02 25 2
7 8 4 4 4 0.05 -0.06 4 4
8 4 6 -5 -5 -0.20 -0.01 -12 0
9 10 19 13 6 0.0 0.09 0 14
10 7 4 -42 -3 0.34 0.07 50 7
II 6 2 3 5 0 0 0.Q2 0.01 0.03 2 I 4
12 12 10 15 9 7 42 -0.02 0.03 -0.10 -3 5 -16
13 9 7 2 II 16 6 -0.06 -0.15 -0.05 -4 -II -4
14 12 II 9 0 27 23 0.07 0.0 -0.01 12 0 -2
15 II 3 I I3 0 II -0.03 0.Q2 -0.07 -3 2 -6
16 2 5 6 -44 -7 -21 0.33 0.07 0.13 43 10 22
17 6 2 0 -7 -6 11 0.13 0.05 -0.07 14 7 -9
18 9 I I 0 6 0 0.05 -0.Q2 0.01 8 -3 I
Mean 9 6 5 -5 2 9 0.14 0.06 -0.02 15 6 -1
± SO 4 5 5 17 10 18 0.23 0.18 0.07 19 11 II
P Value LNS----I LO.05--.J L-O.OI----J 1--0.02---l
1 0.05 ----I 1 NS---1 I NS--...J ! 0.05 ---1
A = change during cold pressor testing; BP = mean arterial pressure; C = control; CSF = coronary sinus blood flow; CVR = coronary vascular
resistance; T5 = 5 minutes after trimazosin; T30 = 30 minutes after trimazosin.
either coronary sinus blood flow (129 ± 34 to 138 ± 37
mllmin, p = NS) or coronary vascular resistance (0.75 ±
0.19 to 0.74 ± 0.18 units, p = NS).
Because of the heterogeneous nature of coronary artery
disease, there is a large variability among cold pressor test-
ing responses. Figure I shows the individual patient re-
sponses during cold pressor testing before and 5 minutes
after trimazosin administration. The increase in coronary
vascular resistance during cold pressor testing was atten-
uated from 14 ± 4 to 6 ± 3% after trimazosin adminis-
tration (p < 0.02). Figure 2 summarizes the changes during
cold pressor testing in mean arterial pressure and coronary
sinus flow and resistance before and after trimazosin. No
changes in arterial-coronary sinus oxygen difference (0.02
± 0.6 versus - 0.15 ± 0.7 mlldl, p = NS) or lactate
extraction (0.11 ± 0.20 versus 0.50 ± 0.42 mEq/liters, p
= NS) during cold pressor testing were found before or
after trimazosin.
Discussion
This study suggests that. selective alpha-adrenergic
blockade with trimazosin attenuates the reflex coronary va-
soconstrictionduring the adrenergic stimulus of cold pressor
testing in patients with coronary artery disease. Our data
are in agreement withexperimental andclinical studies (20,21)
reporting a reduction in coronary vascular resistance after
alpha-receptor blockade, and may be best interpreted by
considering studies relating alpha-adrenoceptor regulation
of coronary blood flow and vasoreactivity.
Figure 1. Individual patient responses during cold pressor testing
before and 5 minutes after trimazosin administration. 6% CVR
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Figure 2. Hemodynamic changes (,0,) during cold pressor testing.
CSBF = coronary sinus blood flow; CVR = coronary vascular
resistance; MAP = mean arterial pressure. 5' and 3D' = 5 and
30 minutes, respectively.
Alpha-adrenergic receptors and coronary vascular
resistance. Alpha-adrenergic tone appears to have a sig-
nificant role in regulating coronary blood flow (3,22-25).
The net result of alpha-adrenoceptor stimulation depends on
the interaction of alpha-receptor subtypes. Activation of
alpha-receptors causes vasoconstriction, while the occu-
pation of the alpha--receptors by norepinephrine inhibits
further release of norepinephrine from postganglionic sym-
pathetic nerve terminals (26,27). Alpha-adrenergical1y me-
diated changes in coronary vascular resistance are capable
of competing with and overcoming opposing metabolic vaso-
dilator influences (6). However, extrapolation of data from
numerous animal studies on the role of alpha-receptors to
human beings is difficult. The in vivo effects of alpha-
receptor activation and blockade on the atherosclerotic hu-
man coronary vasculature are poorly defined. A pathophy-
siologic role for alpha-adrenergic-mediated vasoconstric-
tion is implicated in patients during cold pressor stress (1,12),
coronary vasospasm (10,11), exercise (26,28) and unstable
angina (29). However, nonselective alpha-adrenergic block-
ing agents have not been advocated in patients with coronary
artery disease because of increased myocardial oxygen con-
sumption due to increased inotropy and reflex tachycardia
(i3). In our patients, selective alpha-receptor blockade re-
duced mean arterial pressure approximately 10% without
significant increases in heart rate, arterial norepinephrine
concentration or heart rate-pressure product (as an index of
myocardial oxygen demand).
Mechanisms. The mechanism responsible for the ab-
normal vasoconstrictor response during adrenergic stimu-
lation in patients with coronary artery disease is unclear.
Alpha-mediated vasoconstriction may involve large epicar-
dial vessels, precapillary arterioles or intramyocardial cap-
illaries to different degrees depending on regional differ-
ences in alpha-adrenoceptor concentration, distribution and
sensitivity (22,24,30-32). Autoregulation cannot be dis-
counted as a vasodilator mechanism when constant coronary
blood flow is maintained despite reduced arterial pressure.
We do not believe that metabolic autoregulation of coronary
blood flow alone was responsible for the changes in coronary
resistance observed during cold pressor testing after tri-
mazosin administration. Trimazosin administration was not
associated with a significant decrease in the heart rate-blood
pressure product or a narrowing of the arterial-coronary
sinus oxygen difference during cold pressor testing to sug-
gest reduced metabolic myocardial demand. It is possible
that the lower initial arterial pressure with a relative decrease
in myocardial oxygen demand alters the response of the
coronary bed to the cold pressor vasoconstrictor stimulus.
There was no correlation between initial mean arterial pres-
sure and change in coronary vascular resistance during cold
pressor testing. It also appears unlikely that trimazosin should
alter coronary vascular resistance by any direct effect on
vascular smooth muscle (33).
Trimazosin appears to attenuate vascular resistance com-
ponents in both the coronary circulation and systemic arterial
bed. After trimazosin administration during cold pressor
testing, there is a somewhat greater reduction of coronary
vascular resistance compared with the systemic pressure
response. The reason for this differential effect is unclear,
but it may be due to differences in the distribution, number
and predominant alpha-adrenoceptor subtype in the coronary
compared with the peripheral vasculature (24,34,35).
Selection of alphaj-receptor blocking agent.
Trirnazosin, unlike prazosin, can be administered intrave-
nously and appears to be a more potent coronary vasodilator.
Studies in the conscious dog (20,21,36-39) comparing non-
selective alpha-receptor blockade with phentolamine with
prazosin and trimazosin showed that all three agents reduced
systemic arterial pressure, but coronary resistance decreased
significantly more with trimazosin than with either prazosin
or phentolamine. Specific doses of the alpha-receptor
blocking drug, trimazosin, in human beings have been em-
pirically determined. Data from our preliminary studies and
those of others (36,38) indicated that a modest reduction of
mean arterial pressure without reflex changes in heart rate
occurs with the doses used for this study. No significant
side effects of tachycardia or hypotension were seen with
100 mg of intravenous trimazosin. Because alpha--receptor
stimulation inhibits release of norepinephrine into the neural
synapse during sympathetic impulse transmission, a four-
to fivefold increase in circulating norepinephrine (13,26)
would be expected if alpha--receptor blockade occurred.
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elicit an increase in arterial norepinephrine concentration,
excluding significant presynaptic blocking action.
Study limitations. Certain limitations of ths study should
be noted. Cold pressor testing is an artificial stimulus and
may be difficult to extrapolate to clinical correlations; how-
ever, it consistently increases coronary vascular resistance
in patients with significant coronary artery disease and pro-
vides a reproducible model to assess changes in human
coronary resistance. Variable coronary resistance responses
have been observed (40) in patients with lesser degrees of
coronary artery disease during cold pressor testing. The cold
pressor induced-coronary vascular resistance responses of
the five patients with minimal and single vessel coronary
artery disease were not significantly different from the group
data.
One major limitation of this study was the evaluation of
only global coronary vascular resistance responses to tri-
mazosin. Regional coronary vascular resistance responses
to alpha-receptor blockade may differ from total coronary
vascular resistance depending on several factors, such as
extent of coronary disease, degree of collateral blood flow
and regional autoregulatory capacity. In our patients, tri-
mazosin may have blunted vasoconstriction in diseased ar-
terial segments to a different degree than in normal segments
with the net result of a small increase in global coronary
sinus flow and a decrease in coronary vascular resistance.
Further investigation into regional changes in coronary re-
sistance after alpha-receptor blockade is warranted.
Thermodilution coronary sinus blood flow measurements
can be affected by small changes in catheter position. Rel-
ative changes in flow and resistance have therefore been
used to indicate directional effects and the interpretation of
these data need not depend on the absolute magnitude of
the changes in coronary vascular resistance. Studies in which
right atrial reflux, flow signal artifacts or extrasystoles ap-
peared during measurements were excluded from analysis
(41).
Concurrent effects of other pharmacologic agents com-
plicate the interpretation ofchanges in coronary resistance.
Resolution of preexisting beta-adrenergic blockade after 18
hours may be incomplete, especially in patients taking long-
acting beta-receptor blocking drugs (42,43). However, any
residual beta-receptor blockade would be expected to aug-
ment the changes in coronary vascular resistance during cold
pressor testing (12). Thus, changes in coronary vascular
resistance after administration of trimazosin would be more
significant than in the complete absence of beta-receptor
blockade. Although reported to abolish coronary vasospasm
(44), atropine did not alter coronary vasomotor responses
during cold pressor testing (12) and, in this study, was a
constant factor for all patients.
Clinical significance. Although selective alpha-recep-
tor blockade with trimazosin can attenuate the increase in
coronary vascular resistance during adrenergic stimulation,
the clinical significance of this observation for patients with
coronary artery disease has yet to be determined. Indeed,
alpha I-receptor blockade with prazosin has no obvious ben-
eficial effects in patients with variant angina (45,46) and in
one study (47), has been reported to exacerbate classic an-
gina pectoris. In a subset of patients with coronary artery
disease in whom a vasodilator is indicated, selective alphal-
receptor blockade may have a potential advantage over other
vasodilators, such as hydralazine or nonselective alpha-re-
ceptor blocking drugs. Trimazosin, in addition to attenua-
tion of coronary vascular resistance, appears to result in a
lesser degree of peripheral norepinephrine release and thus,
potentially, less augmentation of heart rate and factors in-
creasing myocardial oxygen demand.
We thank William Grossman, MD for his assistance in the planning of
this project.
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